Key result
Manual thrombectomy with glycoprotein IIb/IIIa inhibitors in STEMI patients with intracoronary thrombus is more expensive but achieves clinical outcomes comparable to patients without thrombus.
Why the study?
Does manual thrombectomy with glycoprotein IIB/IIIA inhibitors increase real-world costs compared to angioplasty alone in STEMI patients?
Cohort (n=107)
Does manual thrombectomy with glycoprotein IIB/IIIA inhibitors increase real-world costs compared to angioplasty alone in STEMI patients?
Manual thrombectomy combined with glycoprotein IIB/IIIA inhibitors in STEMI patients with intracoronary thrombus increases procedural costs but may be cost-effective by achieving clinical outcomes comparable to lower-risk patients.
Answers are grounded in this paper and cite their sources.
May support adjunctive manual thrombectomy plus GP IIb/IIIa inhibitors in STEMI with thrombus despite higher costs; leaves open randomized confirmation of outcomes.
AIM: Study was aimed to assess the real-world costs of manual thrombectomy (MT) in selected ST-segment elevation myocardial infarction patients with intracoronary thrombus (IT). METHODS: Study group (IT+) comprised 51 patients with MT applied and control group (IT-) comprised 56 patients without IT who underwent angioplasty alone. Costs comprised hospital care and cost of disposable materials used during primary angioplasty. RESULTS: Complex management of patients with IT is more expensive, though allows to achieve clinical outcomes comparable to low-risk ST-segment elevation myocardial infarction patients without IT. CONCLUSION: A complex pharmaco-interventional strategy, with glycoprotein IIB/IIIA inhibitor and MT, though more expensive, may prove cost-effective.
No takes yet. Share an insight, caveat, or question.
Pigoń et al. (2018) conducted a cohort in ST-segment elevation myocardial infarction (n=107). Manual thrombectomy and glycoprotein IIB/IIIA inhibitor vs. Angioplasty alone was evaluated on Real-world costs of hospital care and disposable materials. Manual thrombectomy with glycoprotein IIb/IIIa inhibitors in STEMI patients with intracoronary thrombus is more expensive but achieves clinical outcomes comparable to patients without thrombus.
Synapse has enriched 10 related papers. Consider them for comparative context: